stockrow
Saturday 7 November 2026
Export CGEM’s income statement to Excel — free account
Cullinan Therapeutics, Inc.
CGEM Healthcare Biotechnology
- EPS
- +24.3%
- Free cash flow
- +33.7%
Quarter to June 2026, against a year earlier
11.34
0.54
+5.00%
Follow CGEM
Alert me
Cullinan Therapeutics, Inc. (CGEM) P/E ratio
Cullinan Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 9.9× (June 2023) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2021 | 0.0× | — |
Against its own ten years
Low 0.0×
High 9.9×
Ten-year median
0.0×
Current reading's percentile
83
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DNA Ginkgo Bioworks Holdings, Inc. compare | n/m |
| SANA Sana Biotechnology, Inc. compare | n/m |
| SLDB Solid Biosciences Inc. compare | n/m |
| ACHV Achieve Life Sciences, Inc. compare | n/m |
| LXRX Lexicon Pharmaceuticals, Inc. compare | n/m |
| OABI OmniAb, Inc. compare | n/m |
| AURA Aura Biosciences, Inc. compare | n/m |
| CGEM Cullinan Therapeutics, Inc. | n/m |
| ATTO Attovia Therapeutics, Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)